Loading…
← CockpitCompetitor Analysis › PVLA Palvella Therapeutics, Inc.Open in the cockpit ↗

Palvella Therapeutics, Inc.PVLACompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops topical therapies for rare, serious genetic skin diseases, led by a treatment for lymphatic malformations.

Momentum leader 86
Mkt cap
$2.14B
US dollars, full cap
Free float
64%
of shares outstanding
$/day
$42.7M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 6.6%
Hurdle
n/a
no reverse DCF
Next earnings
138 days
5 Apr 2027
Close · USD$146.58
1D+1.5%
1W-10.6%
1M+18.3%
3M+2.8%
6M+26.9%
YTD+40.0%
1Y+79.5%
ATR %6.3%
Beta1.57
52w lowhigh18.5% off high

What Palvella Therapeutics does

Develops topical therapies for rare, serious genetic skin diseases, led by a treatment for lymphatic malformations.

No product to sell yet and no revenue; it is funded by raising capital, and value rests on a topical rapamycin gel clearing its late-stage trial and FDA review for lymphatic malformations. Rare-disease drugs are sold to a small group of specialists, so launch economics rest on a small patient pool.

Products and services

  • QTORIN rapamycin (microcystic lymphatic malformations)
  • Pipeline in pachyonychia congenita

Customers

  • Dermatologists (post-approval)

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Rare genetic skin disease therapeutics

What could go right

  • First approved treatment in an underserved niche
  • Orphan drug pricing potential

What could go wrong

  • Small addressable patient populations
  • Clinical trial and regulatory timeline risk

Moat: none (IP / patents). Addresses rare skin diseases with no approved treatments, but is clinical-stage with small target populations.

Headquarters: Wayne, Pennsylvania, US · Founded: 2015 · Employees: 29

Named competitors

Palvella Therapeutics at a glance

Size Palvella Therapeutics (PVLA) is a United States Health Care company (Biotechnology) with a market value of $2.14B, the 1730th largest of 3,085 United States companies the cockpit tracks. Shares closed at $146.58 on 18 Nov 2026.

Performance Over six months the shares gained 26.9%, against -10.8% for the median peer and -2.2% for the United States market (cap-weighted) — 7th highest of 20 in its peer set.

Growth Revenue fell 100.0% over the last twelve months (peer median +9.4%).

Short interest Short interest is 17.8% of the free float (30 Oct 2026).

Next results Next results expected around 5 Apr 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026PVLA 126Peer median 92
Six months, rebased to 100: Palvella Therapeutics against the median of its 20 peers (local-currency closes).

Palvella Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$25.9M
Revenue growth———-100%—
Gross profit$0$0$0$0$23.1M
EBITDAn/a-$38.6M-$14.1M-$11.9M-$40.7M
Net income-$75.0M-$41.7M-$17.4M$18.7M-$33.3M
Free cash flown/a-$25.0M-$10.8M-$13.7M-$61.0M
Capital expendituren/a$0$0$0$1.04M
Total debtn/a$18.4M$11.9M$78.7M$13.1M

Quarterly statements and history in the cockpit →

Palvella Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%+300%0%+50%ZEAL300676CLDXALMRBEAMPHVS302440VIMIANRCUS300255MRVIREPLSEPNPVLA6-month return →1-month return →
Up and to the right = strong over both horizons. Palvella Therapeutics is the large dot.

Palvella Therapeutics competitors and peer comparison

Head to head with its named competitors (PVLA vs KRYS)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Palvella Therapeutics PVLA$2.14B+27%-100%n/an/an/a
Krystal Biotech KRYS$9.34B+4%+26%48%18.0×13.1%

How Palvella Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Palvella Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasurePVLAPeer medianRank in peer set
1-month return+18.3%-4.9%2nd highest of 21
6-month return+26.9%-10.8%7th highest of 20
Distance from 52-week high-18.5%-34.1%5th highest of 21
Revenue growth (TTM)-100.0%+9.4%2nd lowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Palvella Therapeutics PVLAUnited States$2.14B+27%-100%n/an/an/an/a
Zealand Pharma A/S ZEAL.CODenmark$2.16B-30%-50%46%0.4×n/an/a
BGI Genomics 300676.SZChina$2.13B-15%0%-14%3.2×n/an/a
Celldex Therapeutics CLDXUnited States$2.16B-11%-94%-211,685%9,677.0×n/an/a
Alamar Biosciences ALMRUnited States$2.12B+51%+195%-42%26.1×n/an/a
Beam Therapeutics BEAMUnited States$2.17B-22%+163%-268%9.4×n/an/a
Evopoint Biosciences 688837.SSChina$2.08Bn/an/an/a53.6×n/an/a
Pharvaris PHVSUnited States$2.21B+7%n/an/an/an/an/a
SKBS 302440.KSSouth Korea$2.25B-12%+11%-23%4.3×n/an/a
Vimian VIMIAN.STSweden$2.26B+51%+8%19%5.0×13.4%+44.5%
Lakefront Biotherapeutics LKFT.ASNetherlands$2.26B+31%+223%64%n/an/an/a
Aurinia Pharmaceuticals AUPHUnited States$2.03B-5%+21%45%5.0×3.5%+41.4%
Arcus Biosciences RCUSUnited States$2.27B-34%-58%-475%17.6×n/an/a
Immunome IMNMUnited States$1.98B-22%-100%n/an/an/an/a
Hebei Changshan Biochemical Pharmaceutical 300255.SZChina$2.33B-59%0%-25%19.4×n/an/a
Trevi Therapeutics TRVIUnited States$1.93B-3%n/an/an/an/an/a
Maravai Lifesciences MRVIUnited States$1.92B+101%+11%-17%10.2×n/an/a
Sinocelltech 688520.SSChina$1.90B-35%-40%-75%13.6×n/an/a
BioCryst Pharmaceuticals BCRXUnited States$1.88B-16%+60%42%2.4×-11.0%+117.9%
Replimune REPLUnited States$1.88B+321%n/an/an/an/an/a
Septerna SEPNUnited States$1.88B+41%+337%-76%14.7×n/an/a

Questions

Who are Palvella Therapeutics's main competitors?
Named competitors: Verrica Pharmaceuticals (private or unlisted), Krystal Biotech (KRYS). The cockpit's measured peer set (industry) also includes Zealand Pharma A/S (ZEAL.CO), BGI Genomics (300676.SZ), Celldex Therapeutics (CLDX), Alamar Biosciences (ALMR), Beam Therapeutics (BEAM), Evopoint Biosciences (688837.SS).
How has Palvella Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned +26.9% against -10.8% for the median peer; over one year +79.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.